
KalVista bags FDA approval for delayed oral HAE drug
KalVista has brought the first oral, on-demand treatment for hereditary angioedema attacks to the US market.
Newsletters and Deep Dive digital magazine
KalVista has brought the first oral, on-demand treatment for hereditary angioedema attacks to the US market.
J&J is hoping the AMPLITUDE study results will make Akeega the first drug in the PARP inhibitor class for castration-sensitive prostate cancer.
The first half of 2025 has been marked by a surge in strategic activity across the global healthcare, life sciences, and biotechnology sectors.
The ABPI is worried about investment in medicines and moves that could limit patient and doctor treatment choice in the NHS 10-year plan.
AstraZeneca passes another milestone in its journey to rebuild Imfinzi's presence in bladder cancer, a key growth driver for the drug.
Editor's Picks
Newsletters and Deep Dive
digital magazine